Trial · NCT05797948
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05797948, Not applicable, Unknown, The First Affiliated Hospital of Soochow University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. Trials, record NCT05797948. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05797948
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- NCT number
- NCT05797948
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 20 participants, estimated
- Lead sponsor
- The First Affiliated Hospital of Soochow University
- Conditions
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Interventions
- Obinutuzumab, Zanubrutinib, Lenalidomide, CD19/CD22 CAR-T, Azacitidine For Injection, Fludarabine, Cyclophosphamide
- First posted
- 2023-04-04
- Last updated
- 2023-04-04
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall response rate (ORR) after GZL therapy | At the end of GZL therapy (2-4 cycles, each cycle is 21days) | the rate of patients who achieved CR or PR after GZL therapy |
| Primary | Complete response rate (CRR) after CAR-T | Within 3 months after CAR-T therapy | the best rate of patients who achieved CR after CAR-T therapy |
| Primary | Progression-free survival (PFS) after CAR-T | up to 24 months after the end of last patient's treatment | PFS will be assessed from the GZL combination therapy given to date of progression, relapse, death or end of follow-up. |
| Secondary | Incidence of treatment-emergent adverse events, treatment-related adverse events and serious adverse events | Initiation of GZL therapy until 30 days after CAR-T therapy | The safety and tolerability of the therapeutic regimen measured by the incidence of Treatment-Emergent Adverse Event. |
| Secondary | Overall response rate (ORR) after CAR-T | Within 3 months after CAR-T therapy | The best rate of patients who achieved CR or PR after CAR-T therapy |
| Secondary | Overall survival (OS) after CAR-T | up to 24 months after the end of last patient's treatment | OS will be assessed from the GZL combination therapy given to date of death or end of follow-up. |
| Secondary | Duration of Response(DOR) after CAR-T | up to 24 months after the end of last patient's treatment | DOR will be assessed from the date of CAR-T infusion to the date of progression, relapse, death or end of follow-up |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05797948
GET https://conductscience.org/api/trials/v1/NCT05797948/registered